• January 24, 2022

Happy New Year from Active Biomarkers

A New Year Is starting!

One year back we were all hoping to be "back to normal" thanks to the advent of the vaccines. The January 2022 picture reminds us that the fight against COVID-19 is not over yet.

In these troubled times, being able to rely on a trusted partner is more critical than ever to overcome uncertainties and secure your research programs.

Easier said than done!

Active Biomarkers's team has proven all through 2021 its resilience and reliability. Here is how!
0 day of closing for the second year consecutively thanks to an evolutive business contingency plan and to the strong commitment of our team

1 relocation in brand new private facilities optimized to meet the highest regulatory standards

2 quality certificates in our new site (ISO 9001:2015 and GCLP)

3 new technologies installed, validated, and running to continue offering the latest innovations to your projects (Gyros xPloreTM, Novocyte QuanteonTM 20-color flow cytometer, Simoa HD-X AnalyzerTM)

78 studies supported during the year

1,100 sqm facilities to double our capacities

700,000 data points generated and analyzed

But nothing of this would have been possible without your continued trust and support!

We wish you all an exciting, successful and above all, beyond-COVID New Year!

  • November 15, 2021

Need to track circulating neurological biomarkers?

For clinical monitoring, patient stratification, documenting target engagement, leverage our ULTRASENSTITIVE and MULTIPLEX assays.

Click here to learn more

  • June 15, 2021

The Vaccine Bioanalytical Toolbox

Wanted or unwanted? Check the impact of your vaccine candidate on patients' immune system thanks to our comprehensive bioanalytical toolbox.


  • June 15, 2021

Ella system is Active now! ACTivate your biomarker analyses

Fast and flexible! Translate your precious and limited samples into reliable data with the Ella™ multiplex system. Just ACT!

  • June 15, 2021

Cytokine Storm Analyses

Assessing the risk of cytokine storm is of the highest importance when developing any new immunotherapy.

Early detection and timely reporting are crucial for patient safety.

Discover how we can help you here

  • March 9, 2021

State-of-the-art flow cytometry technology

Active Biomarkers is strengthening its Flow Cytometry capabilities with Novocyte Quanteon (Agilent) technology for faster immune system analysis.

- 20 color configuration

- save precious samples & time

- sophisticated and comprehensive multi-parameter analyses